Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Launched by ABBVIE · Nov 19, 2021
Trial Information
Current as of May 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • - Presence of Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) symptoms for at least 6 months, diagnosed by the investigator as IC/BPS, and confirmed dominant bladder derived pain.
- Exclusion Criteria:
- • - History or current diagnosis of Hunner Lesions.
About Abbvie
AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Homewood, Alabama, United States
Mobile, Alabama, United States
Los Angeles, California, United States
San Diego, California, United States
West Hollywood, California, United States
Farmington, Connecticut, United States
Washington, District Of Columbia, United States
Bradenton, Florida, United States
Pompano Beach, Florida, United States
Shreveport, Louisiana, United States
Watertown, Massachusetts, United States
Las Vegas, Nevada, United States
Cheektowaga, New York, United States
New Hyde Park, New York, United States
New York, New York, United States
New York, New York, United States
New York, New York, United States
Warwick, New York, United States
Winston Salem, North Carolina, United States
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Oakwood, Ohio, United States
Allentown, Pennsylvania, United States
Bala Cynwyd, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Charleston, South Carolina, United States
Chattanooga, Tennessee, United States
Nashville, Tennessee, United States
Dallas, Texas, United States
Houston, Texas, United States
Houston, Texas, United States
Alexandria, Virginia, United States
Suffolk, Virginia, United States
Virginia Beach, Virginia, United States
Calgary, Alberta, Canada
Kingston, Ontario, Canada
Toronto, Ontario, Canada
Sherbrooke, Quebec, Canada
Mobile, Alabama, United States
Hamlet, North Carolina, United States
Shreveport, Louisiana, United States
Avon, Ohio, United States
Pearland, Texas, United States
Mobile, Alabama, United States
Pomona, California, United States
Santa Ana, California, United States
Murrieta, California, United States
Buena Park, California, United States
Myrtle Beach, South Carolina, United States
Farmington, Connecticut, United States
Cleveland, Ohio, United States
Farmington, Connecticut, United States
Chattanooga, Tennessee, United States
Los Angeles, California, United States
Chattanooga, Tennessee, United States
Charleston, South Carolina, United States
New York, New York, United States
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
ABBVIE INC.
Study Director
AbbVie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials